Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammary Analogue Secretory Carcinoma | 1 | 2023 | 9 | 0.940 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2023 | 489 | 0.670 |
Why?
|
| Oropharyngeal Neoplasms | 5 | 2022 | 1105 | 0.640 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 476 | 0.510 |
Why?
|
| Leukocytosis | 1 | 2014 | 112 | 0.460 |
Why?
|
| Splenic Neoplasms | 1 | 2014 | 119 | 0.450 |
Why?
|
| Hemangiosarcoma | 2 | 2014 | 234 | 0.450 |
Why?
|
| Carcinoma | 1 | 2023 | 2578 | 0.410 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 242 | 0.340 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2011 | 184 | 0.330 |
Why?
|
| Scleroderma, Systemic | 3 | 2016 | 134 | 0.330 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 846 | 0.330 |
Why?
|
| Anemia | 1 | 2014 | 689 | 0.320 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2005 | 37 | 0.250 |
Why?
|
| Fatal Outcome | 3 | 2014 | 829 | 0.240 |
Why?
|
| Gingiva | 1 | 2023 | 18 | 0.240 |
Why?
|
| Influenza, Human | 1 | 2011 | 925 | 0.230 |
Why?
|
| Lung | 2 | 2011 | 3151 | 0.220 |
Why?
|
| Gene Fusion | 1 | 2023 | 209 | 0.210 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 980 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 2390 | 0.170 |
Why?
|
| Thrombosis | 1 | 2005 | 781 | 0.160 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 755 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2019 | 5437 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2232 | 0.160 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 1245 | 0.160 |
Why?
|
| Semaphorins | 1 | 2016 | 38 | 0.150 |
Why?
|
| Fibroblasts | 3 | 2016 | 1682 | 0.140 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 447 | 0.130 |
Why?
|
| HLA-DRB1 Chains | 1 | 2014 | 82 | 0.120 |
Why?
|
| Demography | 1 | 2016 | 435 | 0.120 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 4844 | 0.120 |
Why?
|
| Protein Transport | 1 | 2016 | 734 | 0.120 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 120 | 0.110 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 374 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 554 | 0.110 |
Why?
|
| Skin | 2 | 2010 | 1259 | 0.100 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2011 | 57 | 0.100 |
Why?
|
| Biocatalysis | 1 | 2011 | 63 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4298 | 0.100 |
Why?
|
| Osteonectin | 1 | 2010 | 53 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 1450 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 4988 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 1265 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 3976 | 0.090 |
Why?
|
| Genotype | 2 | 2016 | 4109 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 10001 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 1429 | 0.080 |
Why?
|
| Pulmonary Fibrosis | 1 | 2010 | 170 | 0.080 |
Why?
|
| Humans | 17 | 2023 | 261506 | 0.080 |
Why?
|
| Middle Aged | 8 | 2019 | 86204 | 0.080 |
Why?
|
| Male | 12 | 2019 | 123000 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 2216 | 0.080 |
Why?
|
| Veterans | 2 | 2015 | 1641 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 13658 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 7551 | 0.070 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 1946 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2011 | 1620 | 0.070 |
Why?
|
| Catastrophic Illness | 1 | 2005 | 4 | 0.070 |
Why?
|
| Fenretinide | 1 | 2005 | 96 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 5178 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 10331 | 0.070 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2005 | 26 | 0.070 |
Why?
|
| HIV Infections | 1 | 2018 | 2134 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2005 | 77 | 0.060 |
Why?
|
| Prognosis | 3 | 2022 | 21713 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 3343 | 0.060 |
Why?
|
| Vascular Neoplasms | 1 | 2005 | 114 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2005 | 145 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 200 | 0.060 |
Why?
|
| Multiple Organ Failure | 1 | 2005 | 177 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 483 | 0.060 |
Why?
|
| Adult | 7 | 2018 | 77950 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 4821 | 0.050 |
Why?
|
| Risk Factors | 2 | 2016 | 17523 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2005 | 876 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2005 | 499 | 0.050 |
Why?
|
| Female | 10 | 2019 | 141928 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 5539 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 10035 | 0.050 |
Why?
|
| Aged | 6 | 2019 | 70117 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 5061 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 624 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2019 | 180 | 0.040 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2016 | 16 | 0.040 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2016 | 34 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2016 | 50 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2016 | 58 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2016 | 182 | 0.030 |
Why?
|
| Smoking | 2 | 2015 | 2440 | 0.030 |
Why?
|
| Transfection | 2 | 2011 | 2944 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 15 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2005 | 2819 | 0.030 |
Why?
|
| Gene Expression | 2 | 2016 | 3570 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 460 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 1154 | 0.030 |
Why?
|
| Carcinogens | 1 | 2015 | 384 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 256 | 0.030 |
Why?
|
| China | 1 | 2014 | 606 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 397 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 848 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 285 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 833 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 551 | 0.030 |
Why?
|
| Diet | 1 | 2019 | 1440 | 0.020 |
Why?
|
| Sumoylation | 1 | 2011 | 84 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 5159 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2010 | 45 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 591 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2010 | 171 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2010 | 204 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 2466 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5673 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2010 | 229 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 7548 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1217 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 2086 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3981 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2010 | 837 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 14551 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 793 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6207 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3536 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 289 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 3639 | 0.020 |
Why?
|
| Clone Cells | 1 | 2005 | 555 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4549 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2016 | 7226 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 14889 | 0.010 |
Why?
|
| Texas | 1 | 2015 | 6311 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2015 | 9180 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 14289 | 0.010 |
Why?
|
| Mice | 2 | 2016 | 34495 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 9244 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 6869 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 141 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2015 | 37905 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 4143 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 5637 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 869 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 6942 | 0.010 |
Why?
|
| Animals | 2 | 2016 | 59536 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 2489 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 7222 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 32848 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 4078 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 8873 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 15694 | 0.000 |
Why?
|